Marcus O. Butler

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

F. Stephen Hodi, Martín C. Mihm, Robert J. Soiffer et al. · Proceedings of the National Academy of Sciences · 2003 · 997 citations · Full text

Life Sciences, Immunology, Oncology +17

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski et al. · New England Journal of Medicine · 2021 · 878 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

F. Stephen Hodi, Marcus O. Butler, Darryl A. Oble et al. · Proceedings of the National Academy of Sciences · 2008 · 648 citations · Full text

Medicine, Immunology, Oncology +17

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

Yuki Kagoya, Shinya Tanaka, Tingxi Guo et al. · Nature Medicine · 2018 · 600 citations

Life Sciences, Immunology, Oncology +14